Navigation Links
Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
Date:10/3/2007

SAN DIEGO, Oct. 3 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at BIO InvestorForum 2007 on Wednesday, October 10, 2007, at 11:45 a.m. PDT (2:45 p.m. EDT). The conference is being held at The Palace Hotel in San Francisco.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys Pharmaceuticals, Inc. will present an overview of Anadys and an update on its two development-stage product candidates, ANA598 and ANA773.

The presentation will be simultaneously webcast and can be accessed on the Company's website at http://www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be archived until October 24, 2007.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company committed to advancing patient care by developing and commercializing novel small molecule medicines for the treatment of hepatitis C virus (HCV) infection and cancer. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of HCV and ANA773, an oral TLR7 agonist prodrug for cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop and commercialize novel small molecule medicines for the treatment of HCV and cancer. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical studies may not be predictive of future results, and Anadys cannot provide any assurances that any of its product candidates will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2006 and Anadys' Form 10-Q for the quarter ended June 30, 2007. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... CO (PRWEB) , ... April 24, 2017 , ... ... American Educational Research Association’s Outstanding Public Communication of Education Research Award. The award ... public, including education communities. It recognizes a scholar who has demonstrated the capacity ...
(Date:4/24/2017)... ... April 24, 2017 , ... Sean Fay is the ... Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which sold more than ... marketer in the last 25 years. , Now, due to changes in the broadcast ...
(Date:4/24/2017)... ... April 24, 2017 , ... The ... public support to bring their novel lifesaving device for the everyday use of ... medical-grade sensors, specially designed to read a child’s vital signs, and detect unusual ...
(Date:4/24/2017)... ... April 24, 2017 , ... According to the ... now claim the lives of 62 Americans each day.(1) Yet since 2011, the ... distributors, pharmacies and prescribers by more than half.(2) Novus Medical Detox Center ...
(Date:4/24/2017)... ... 2017 , ... Pitavastatin, a relatively new statin, has relevance ... to have significant interactions with antiretroviral therapy (ART). Among people living with ... inflammation in the bloodstream. , While lowering cholesterol and dampening inflammation are beneficial ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
(Date:4/19/2017)...  New research provides evidence that an old drug may ... study released today that will be presented at the ... Boston , April 22 to 28, 2017. ... disease, the oral drug levodopa has long been considered the ... the disease progresses, the effects of the medication can partially ...
(Date:4/19/2017)... 19, 2017  SARES•REGIS Group leased the first ... at Conejo Spectrum Business Park in ... Biotherapeutics, Inc. , a biopharmaceutical company developing meaningful ... that have been underserved by scientific innovation, with ... cancer, autoimmune and infectious disease. Before ...
Breaking Medicine Technology: